Reports that the U.S. Food and Drug Administration advisory committee has certified Corixa's Bexxar as effective against relapsed non-Hodgkin's lymphoma. Patent litigation involving Corixa and IDEC Pharmaceuticals; Factors limiting the sales of IDEC Pharmaceutical's competing antibody Zevalin.